4.7 Article

Attenuation of diabetic nephropathy in diabetes rats induced by streptozotocin by regulating the endoplasmic reticulum stress inflammatory response

期刊

METABOLISM-CLINICAL AND EXPERIMENTAL
卷 60, 期 5, 页码 594-603

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.metabol.2010.07.021

关键词

-

资金

  1. National Nature Science Foundation of China [30570763]
  2. Scientific Research Foundation for Returned Overseas Chinese Scholars, Third Military Medical University, China [XG200555]

向作者/读者索取更多资源

The endoplasmic reticulum (ER) is capable of sensing metabolic and stress parameters and integrating intra- and extracellular signals to support a coordinated cell response. In the present study, we verified the hypothesis that 4-phenylbutyric acid (4-PBA), a chemical chaperone, prevented the progression of diabetic nephropathy (DN). Male Sprague-Dawley rats were randomly divided into 3 groups: a normal control group, a DN group, and a DN model plus 4-PBA treatment group (PBA). The DN model was induced by injection of streptozotocin with uninephrectomy. The dosage of 4-PBA treatment was gavaged at a dose of 1 g/kg body weight each day for 12 weeks. The expression of the ER stress indicators significantly increased in the kidney of DN rats within the indicated period. Moreover, the expression of phosphorylated c-JUN NH2-terminal kinase, the monocyte chemoattractant protein-1, and the final fibrotic effector all elevated markedly in the kidney of DN rats. Urinary protein excretion rate and the concentration of urinary monocyte chemoattractant protein-1 were higher than those in the normal control group. Treatment with 4-PBA can suppress the expression of the glucose-regulated protein 78 and the phosphorylation of the PKR-like ER kinase, both of which are ER stress indicators; renoinflammatory signal; and the expression of inflammatory cytokines and fibrosis factors. It also can inhibit the increase in urinary protein excretion rate and urinary monocyte chemoattractant protein-1. In conclusion, 4-PBA exerts a marked renoprotective effect possibly due to modulating ER stress and related inflammatory cascade. Crown Copyright (C) 2011 Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Article Endocrinology & Metabolism

Upper small intestine microbiome in obesity and related metabolic disorders: A new field of investigation

Emilie Steinbach, Davide Masi, Agnes Ribeiro, Patricia Serradas, Tiphaine Le Roy, Karine Clement

Summary: The study of the gut microbiome is crucial for understanding and treating metabolic diseases. While research on the fecal microbiome has provided valuable insights, relying solely on this may not be enough to draw comprehensive conclusions. The microbiome in the proximal part of the small intestine may play a significant role in metabolic regulation, but further exploration is needed due to limited accessibility.

METABOLISM-CLINICAL AND EXPERIMENTAL (2024)

Article Endocrinology & Metabolism

Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4

Evangelia Chavdoula, Vollter Anastas, Alessandro La Ferlita, Julian Aldana, Giuseppe Carota, Mariarita Spampinato, Burak Soysal, Ilaria Cosentini, Sameer Parashar, Anuvrat Sircar, Giovanni Nigita, Lalit Sehgal, Michael A. Freitas, Philip N. Tsichlis

Summary: This study reveals the important role of KDM2B in triple-negative breast cancer (TNBC). KDM2B affects cellular resistance to oxidative stress by regulating a network of genes and metabolic enzymes, in collaboration with ATF4 and MYC. Additionally, high expression of KDM2B is associated with poor prognosis in patients.

METABOLISM-CLINICAL AND EXPERIMENTAL (2024)

Article Endocrinology & Metabolism

Statin therapy in individuals with intermediate cardiovascular risk

Joongmin Kim, Hyeongsoo Kim, Sang Hyun Park, Yura Kang, Kyungdo Han, Sang-Hak Lee

Summary: This study aimed to investigate the optimal LDL-C level after statin therapy in individuals with intermediate cardiovascular risk. The results showed that achieving LDL-C levels <120 mg/dL after statin therapy could lower the event risk.

METABOLISM-CLINICAL AND EXPERIMENTAL (2024)

Review Endocrinology & Metabolism

Glucocorticoids and intrauterine programming of nonalcoholic fatty liver disease

Ze Chen, Li -Ping Xia, Lang Shen, Dan Xu, Yu Guo, Hui Wang

Summary: Accumulating evidence suggests that NAFLD has an intrauterine origin, with adverse prenatal environments and glucocorticoid exposure playing a crucial role in the developmental programming of fetal hepatic lipid metabolism. The offspring's glucocorticoid-insulin-like growth factor 1 (GC-IGF1) axis is programmed in utero, leading to postnatal catch-up growth and disrupted glucose and lipid metabolism, increasing susceptibility to NAFLD. Mismatch between intrauterine and postnatal environments can further disturb the programmed endocrine axes and accelerate the onset of NAFLD.

METABOLISM-CLINICAL AND EXPERIMENTAL (2024)

Article Endocrinology & Metabolism

CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease

Fuwen Zuo, Youzhao Wang, Xinlei Xu, Ruihao Ding, Wei Tang, Yu Sun, Xiaojie Wang, Yan Zhang, Jichao Wu, Yusheng Xie, Min Liu, Ziying Wang, Fan Yi

Summary: This study investigates the role of CCDC92 in the pathogenesis of diabetic kidney disease (DKD). The expression of CCDC92 was found to increase in kidney biopsies from patients with DKD and was correlated with glomerular lipid accumulation. Animal studies further confirmed the induction of CCDC92 in the kidney, particularly in podocytes, and the podocyte-specific deletion of Ccdc92 ameliorated podocyte injury and lipid deposition. CCDC92 was shown to promote podocyte lipotoxicity through ABCA1 signaling-mediated lipid homeostasis. Therefore, CCDC92 may serve as a potential biomarker of podocyte injury in DKD and targeting CCDC92 could be an innovative therapeutic strategy for DKD patients.

METABOLISM-CLINICAL AND EXPERIMENTAL (2024)

Review Endocrinology & Metabolism

Brown adipose tissue-derived metabolites and their role in regulating metabolism

Khanyisani Ziqubu, Phiwayinkosi Dludla, Sihle E. Mabhida, Babalwa U. Jack, Susanne Keipert, Martin Jastroch, Sithandiwe E. Mazibuko-Mbeje

Summary: The discovery and revival of brown adipose tissue (BAT) in adult humans have opened up new possibilities for treating obesity and metabolic diseases. BAT not only plays a role in generating heat, but also secretes signaling molecules known as batokines, which regulate overall metabolism. This review highlights the importance of BAT-derived metabolites in controlling thermogenesis, substrate metabolism, and other biological processes, as well as their potential to alleviate obesity and related metabolic complications.

METABOLISM-CLINICAL AND EXPERIMENTAL (2024)